Safety, tolerability, and pharmacokinetics (PK) of rilotumumab (R) combined with cisplatin (C) and capecitabine (X) in Japanese patients (pts) with MET-positive metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.